- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
April 15, 2015 (MedicalXPress) — Children with type 1diabetes run almost five times the risk of being admitted to hospital for any reason as their peers, finds research published in the online journal BMJ Open.
Pre-schoolers and those from disadvantaged backgrounds are most at risk, the findings indicate.
The number of new cases of childhood type 1 diabetes has been rising steadily by around 3-4% a year, the evidence shows, and the risk of death among those with the condition un
April 15, 2015 (Healio) - There is no statistical evidence that type 2 diabetes negatively affects immune response to hepatitis B vaccine, according to findings presented at the Annual Conference on Vaccine Research.
In 2011, the Advisory Committee on Immunization Practices recommended that patients aged 19 to 59 years should be vaccinated against HBV as soon as possible after a diagnosis of diabetes, and for
April 15, 2015 (Healio) - Balance and ankle strength could predict spatiotemporal gait in patients with diabetic peripheral neuropathy, according to data recently published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
Researchers conducted a study of 30 patients with diabetic peripheral neuropathy (DPN) and 30 control patients to evalua
April 15, 2015 (USAToday) - Children are slightly more likely to develop autism if their mothers were diagnosed with diabetes early in pregnancy, a new study shows.
Women newly diagnosed with diabetes by the 26th week of pregnancy were 42% more likely to have a child diagnosed with autism, according to the study of more than 322,000 children born between 1995 and 2009.
Overall, about 1% of all children in the study were diagnosed with autism by a median age of age 5½. Hav
April 15, 2015 (Medical Daily) - WASHINGTON (Reuters) - AstraZeneca Plc's diabetes drug Onglyza has a broadly acceptable cardiovascular safety profile but its label should include new information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday.
The recommendation did not include any restrictions on prescribing the drug, sending AstraZeneca's shares up 3.26 percent to $71.